PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

The combination of pemetrexed and sorafenib has significant clinical activity against a wide variety of tumor types in patients and the present studies were performed to determine whether sildenafil enhances the killing potential of [pemetrexed + sorafenib]. In multiple genetically diverse lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355112/
https://www.ncbi.nlm.nih.gov/pubmed/28088782
http://dx.doi.org/10.18632/oncotarget.14562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355112/
https://www.ncbi.nlm.nih.gov/pubmed/28088782
http://dx.doi.org/10.18632/oncotarget.14562

Ejemplares similares